Alli

January 1st, 2010 by admin Leave a reply »

By Best Weight Loss Review

Alli 84 Pack Fat Blocker

Order Alli 84 Pack!

About Alli Diet Pills

Alli is an over-the-counter diet pill that promises the strength of a prescription diet pill, but in a non-prescription form. Although there was some controversy over its approval by the FDA, it is a safe, effective and popular option for weight loss. At the moment, there are only two products which have been approved by FDA (Alli and Proactol).

The main ingredient in Alli is Orlistat. This ingredient would help you to block your fat intake. If you can’t resist yourself to eat high-fat foods, Alli works great for you.

Actually, Alli is not different with Xenical. You can say that Alli is a half-dozen Xenical. Because Xenical retailers realize their product is too dangerous for their users, so they reduce the ingredients.

Alli Benefits
  • Increase speed of your weight loss
  • Allows sustainable weight loss
  • High success rate
  • FDA approved fat binder
  • Boosts weight loss by up to 50%
  • Decrease the absorption of fat in intestines thus reduce the number of calories absorbed
  • Best used with a healthy diet and regular exercise plans
Alli Side Effects
  • May cause urgent bowel movements, diarrhea and gas with oily spotting, if consumed too much
  • Need to consume other fat-soluble vitamin supplements such as Vit A, D and E
  • May cause allergy

Conclusion:

In our opinion there are better diet pills, without side effects, on the market. We highly recommend Proactol, UniqueHoodia, Pure Acai Berry or Zotrim .

However, if you want to lose weight with Alli , visit link bellow…

Buy Alli 84 Pack

Share and Enjoy:
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Blogplay
  • blogmarks
  • Diigo
  • Hyves
  • LinkaGoGo
  • Netvibes
  • Netvouz
  • NewsVine
  • Reddit
  • StumbleUpon
  • Technorati
  • Tumblr
  • Twitter
  • Yahoo! Buzz
If you enjoyed this post, make sure you subscribe to my RSS feed!
Advertisement

Comments are closed.